These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24346128)

  • 1. Triple-negative breast cancer: molecular subtypes and targeted therapy.
    Hirshfield KM; Ganesan S
    Curr Opin Obstet Gynecol; 2014 Feb; 26(1):34-40. PubMed ID: 24346128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
    Yam C; Mani SA; Moulder SL
    Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
    Toyama T; Yamashita H; Kondo N; Okuda K; Takahashi S; Sasaki H; Sugiura H; Iwase H; Fujii Y
    BMC Cancer; 2008 Oct; 8():309. PubMed ID: 18950515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation.
    Wen YH; Ho A; Patil S; Akram M; Catalano J; Eaton A; Norton L; Benezra R; Brogi E
    Breast Cancer Res Treat; 2012 Aug; 135(1):93-102. PubMed ID: 22538771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.
    Diaz LK; Cryns VL; Symmans WF; Sneige N
    Adv Anat Pathol; 2007 Nov; 14(6):419-30. PubMed ID: 18049131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring novel targets of basal-like breast carcinoma by comparative gene profiling and mechanism analysis.
    Wu YM; Hu W; Wang Y; Wang N; Gao L; Chen ZZ; Zheng WQ
    Breast Cancer Res Treat; 2013 Aug; 141(1):23-32. PubMed ID: 23933801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor.
    Doberstein K; Milde-Langosch K; Bretz NP; Schirmer U; Harari A; Witzel I; Ben-Arie A; Hubalek M; Müller-Holzner E; Reinold S; Zeimet AG; Altevogt P; Fogel M
    BMC Cancer; 2014 Dec; 14():958. PubMed ID: 25510351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A targetable androgen receptor-positive breast cancer subtype hidden among the triple-negative cancers.
    Safarpour D; Tavassoli FA
    Arch Pathol Lab Med; 2015 May; 139(5):612-7. PubMed ID: 25310144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple-negative breast cancers and the human mammary epithelial cell hierarchy.
    Ganesan S; Karantza V; Oza J; Toppmeyer D
    Breast Dis; 2010; 32(1-2):49-61. PubMed ID: 22045329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New targets for triple-negative breast cancer.
    Herold CI; Anders CK
    Oncology (Williston Park); 2013 Sep; 27(9):846-54. PubMed ID: 24282978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers.
    Domagala P; Hybiak J; Rys J; Byrski T; Cybulski C; Lubinski J
    Oncotarget; 2016 Oct; 7(42):68662-68673. PubMed ID: 27626685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The targeted inhibition of Hsp90 by a synthetic small molecule, DPide offers an effective treatment strategy against TNBCs.
    Oh YJ; Park SY; Seo YH
    Oncol Rep; 2018 Apr; 39(4):1775-1782. PubMed ID: 29436674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple Negative Breast Cancer: A Tale of Two Decades.
    Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
    Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.
    Denkert C; Liedtke C; Tutt A; von Minckwitz G
    Lancet; 2017 Jun; 389(10087):2430-2442. PubMed ID: 27939063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers.
    Abdel-Fatah TM; Arora A; Moseley PM; Perry C; Rakha EA; Green AR; Chan SY; Ellis IO; Madhusudan S
    Oncotarget; 2015 Sep; 6(26):21964-78. PubMed ID: 26267318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
    Shapira I; Lee A; Vora R; Budman DR
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):284-92. PubMed ID: 23755891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIM1: a promising target in patients with triple-negative breast cancer.
    Zhao W; Qiu R; Li P; Yang J
    Med Oncol; 2017 Aug; 34(8):142. PubMed ID: 28721678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple-negative breast cancer and the need for new therapeutic targets.
    Engebraaten O; Vollan HKM; Børresen-Dale AL
    Am J Pathol; 2013 Oct; 183(4):1064-1074. PubMed ID: 23920327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
    Bianchini G; Balko JM; Mayer IA; Sanders ME; Gianni L
    Nat Rev Clin Oncol; 2016 Nov; 13(11):674-690. PubMed ID: 27184417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.